Who to call at CRISPR Therapeutics AG, and when
Fundz watches for the moments CRISPR Therapeutics AG starts buying, and tells you who to reach.
- An alert the day CRISPR Therapeutics AG raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at CRISPR Therapeutics AG, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at CRISPR Therapeutics AG. With Fundz connected, it knows.
CRISPR Therapeutics AG
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
crisprtx.comExecutive Summary
Analysis of 8-K filing content
CRISPR Therapeutics promoted Andrew J. Silver from Senior Vice President of Finance to Chief Financial Officer effective October 19, 2026. This leadership transition strengthens financial oversight with an experienced executive who has been with the company since 2018 and brings over 10 years of Big Four accounting experience.
Quick answer
CRISPR Therapeutics AG filed a Form 8-K with the SEC on October 19, 2026 under Item 5.02 (Executive Change). CRISPR Therapeutics promoted Andrew J. Silver from Senior Vice President of Finance to Chief Financial Officer effective October 19, 2026.
- What did CRISPR Therapeutics AG disclose in its 8-K filed October 19, 2026?
- CRISPR Therapeutics promoted Andrew J. Silver from Senior Vice President of Finance to Chief Financial Officer effective October 19, 2026. This leadership transition strengthens financial oversight with an experienced executive who has been with the company since 2018 and brings over 10 years of Big Four accounting experience.
- What does 8-K Item 5.02 (Executive Change) mean?
- A senior executive or director joined, left, or changed roles. Companies generally must file it within four business days of the event.
- Which other companies filed an 8-K Item 5.02 around the same time?
- Village Farms International, Inc. (October 19, 2026), Invesco Capital Management LLC (October 19, 2026), OPAL Fuels Inc. (October 19, 2026) and Neptune Flood Incorporated (October 19, 2026) also filed an Item 5.02 8-K within a week of CRISPR Therapeutics AG.
- Where can I read the original CRISPR Therapeutics AG filing?
- The original filing is on SEC EDGAR (CIK 0001674416), accession number 0001193125-26-425243.
Source: Fundz verified event record.
Other companies that filed an 8-K Item 5.02 (Executive Change) the same week
Analyzed filings with the same item number within 7 days, from SEC EDGAR via Fundz.
- Village Farms International, Inc. (October 19, 2026): Village Farms International appointed Stephen C. Ruffini as Executive Vice President of Mergers & Acquisitions effective October 16, 2026, with a $400,000 annual salary and...
- Invesco Capital Management LLC (October 19, 2026): Invesco Capital Management LLC appointed Lori Anello as Principal Financial and Accounting Officer effective October 22, 2026, following Kelli Gallegos' leave of absence.
- OPAL Fuels Inc. (October 19, 2026): Jonathan Maurer, Co-CEO of OPAL Fuels Inc., announced his retirement effective March 31, 2027, with Adam Comora assuming the role of sole CEO.
- Neptune Flood Incorporated (October 19, 2026): Neptune Flood appointed Cristian Melej, an existing board member with extensive CFO experience at Hingham Institution for Savings, as Chief Financial Officer effective upon filing...
- Fox Corporation (October 19, 2026): Fox Corporation announced the departure of Chief Legal and Policy Officer Adam Ciongoli effective December 1, 2026, and the concurrent appointment of Nicholas Trutanich as General...
- Standex International Corporation (October 19, 2026): Standex International appointed Samantha L. Stoddard as Vice President, Chief Financial Officer, and Treasurer, effective December 1, 2026, with an annual base salary of $575,000...
Key Takeaways
Andrew J. Silver appointed as CFO with immediate effect, also serving as principal financial and accounting officer
Silver has been with CRISPR since October 2018 and was promoted from SVP of Finance, indicating internal continuity and stability
2 more takeaways
Filing Overview
What This Means
CRISPR Therapeutics AG filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.